Pharmaceutical Industry Reports Nonalcoholic Steatohepatitis Treatment Market | Page 2

REPORT DESCRIPTION
Nonalcoholic Steatohepatitis Treatment Market – Overview
Nonalcoholic steatohepatitis (NASH) is a form of nonalcoholic fatty liver disease (NAFLD) in which a person
have hepatitis and inflammation of the liver, and can cause liver damage. NASH can lead to complications, such
as cirrhosis and liver cancer. Patients with NASH have high chance of mortality due to liver-related causes such as
liver failure.
Lifestyle modification, including change in diet and exercise, is the basic therapy recommended for nonalcoholic
fatty liver disease. However, in some cases lifestyle modification is difficult to achieve and to sustain, and
therefore required other treatments including medicine.
Currently available drugs for the treatment of NAFLD were historically been given for other indications. For
instance, Orlistat, a gut lipase inhibitor, is indicated for decrease in the dietary fats absorption. According to the
National Center for Biotechnology Information (NCBI) 2017 study, Orlistat has been approved for treatment of
obesity and is available over the counter in the U.S. for weight loss. Orlistat-mediated weight loss is related with
reduction in hepatic steatosis.